4//SEC Filing
Gheuens Sarah 4
Accession 0001439222-25-000118
CIK 0001439222other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 4:08 PM ET
Size
8.9 KB
Accession
0001439222-25-000118
Insider Transaction Report
Form 4
Gheuens Sarah
Chief Medical Officer
Transactions
- Exercise/Conversion
Common stock
2025-11-11$25.01/sh+2,454$61,375→ 64,181 total - Sale
Common stock
2025-11-11$43.78/sh−2,454$107,436→ 61,727 total - Exercise/Conversion
Stock options (right to buy)
2025-11-11−2,454→ 26,130 totalExercise: $25.01Exp: 2033-03-01→ Common stock (2,454 underlying)
Footnotes (3)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $43.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001881190
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 4:08 PM ET
- Size
- 8.9 KB